Breaking News Instant updates and real-time market news.

VZ

Verizon

$60.35

-0.13 (-0.21%)

05:21
11/04/19
11/04
05:21
11/04/19
05:21

Verizon downgraded to Neutral from Buy at Nomura Instinet

Nomura Instinet analyst Jeffrey Kvaal downgraded Verizon Communications to Neutral from Buy with a $65 price target.

  • 19

    Nov

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 30

    Jan

VZ Verizon
$60.35

-0.13 (-0.21%)

10/16/19
10/16/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Verizon (VZ), Comcast (CMCSA), and AT&T (T) initiated with Market Perform ratings at Bernstein. 2. Inovalon (INOV) initiated with a Buy at Citi. 3. Assembly Biosciences (ASMB) initiated with a Buy at Mizuho. 4. ChromaDex (CDXC) initiated with an Outperform at Oppenheimer. 5. Axsome Therapeutics (AXSM) initiated with a Buy at Guggenheim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/25/19
MOFT
10/25/19
NO CHANGE
Target $57
MOFT
Neutral
MoffettNathanson sees 'worrisome signs' in Verizon's Q3 report
MoffettNathanson analyst Craig Moffett said Verizon still has the industry's highest margins and still boasts the industry's lowest post-paid phone churn rate, but he points to what he sees as "a few worrisome signs" in Verizon's Q3 report despite the company's "solid" subscriber growth metrics. Wireless service margins have started to ease, ARPU growth moved lower for a second straight quarter and churn "has started to move ever so slightly higher," Moffett tells investors in a post-earnings research note. Most "ominously," Verizon is no longer the hands-down winner of the "best network" test, which is now a much more nuanced discussion, according to Moffett, who keeps a Neutral rating and $57 price target on the stock.
10/28/19
GUGG
10/28/19
NO CHANGE
Target $69
GUGG
Buy
Verizon price target raised to $69 from $65 at Guggenheim
Guggenheim analyst Mike McCormack raised his price target for Verizon Communications to $69 from $65 saying the company reported "strong" Q3 Wireless results, with revenue, earnings, and free cash flow coming in ahead of consensus. The analyst maintains a Buy rating on the shares.
10/28/19
ADAM
10/28/19
NO CHANGE
Target $8.5
ADAM
Buy
Inseego price target raised to $8.50 from $7.00 at Canaccord
Canaccord analyst T. Michael Walkley raised his price target on Inseego (INSG) to $8.50 from $7.00. Management decided to increase near-term investments to support additional products for a growing global 5G opportunity. The company launched the industry's first 5G mobile hotspot and Walkley believes volumes will ramp through year-end as Verizon (VZ) launches an increasing number of cities.Walkley reiterated his Buy rating on Inseego shares.

TODAY'S FREE FLY STORIES

AQST

Aquestive Therapeutics

$7.89

-0.13 (-1.62%)

15:25
12/09/19
12/09
15:25
12/09/19
15:25
Conference/Events
Aquestive Therapeutics holds analyst & investor event w/conference call hookup »

Management and Key…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

PTLA

Portola Pharmaceuticals

$28.48

-0.74 (-2.53%)

15:24
12/09/19
12/09
15:24
12/09/19
15:24
Hot Stocks
Portola presents new interim Phase 2a data from study of cerdulatinib »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARQL

ArQule

$19.72

10.045 (103.88%)

15:21
12/09/19
12/09
15:21
12/09/19
15:21
Downgrade
ArQule rating change  »

ArQule downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

TOL

Toll Brothers

$41.50

0.62 (1.52%)

15:19
12/09/19
12/09
15:19
12/09/19
15:19
Options
Toll Brothers options imply 8.6% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
12/09/19
12/09
15:17
12/09/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
12/09/19
12/09
15:16
12/09/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DISH

Dish

$33.53

-0.06 (-0.18%)

15:15
12/09/19
12/09
15:15
12/09/19
15:15
Options
Dish put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGNX

MacroGenics

$9.87

0.19 (1.96%)

15:09
12/09/19
12/09
15:09
12/09/19
15:09
Hot Stocks
MacroGenics announces updated results from Phase 1/2 study of flotetuzumab »

MacroGenics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

MDB

MongoDB

$131.13

-0.09 (-0.07%)

15:04
12/09/19
12/09
15:04
12/09/19
15:04
Options
MongoDB options imply 14.8% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 18

    Dec

IMGN

ImmunoGen

$4.06

0.195 (5.05%)

15:03
12/09/19
12/09
15:03
12/09/19
15:03
Hot Stocks
ImmunoGen presents updated findings from Phase 1 study of IMGN632 at ASH meeting »

ImmunoGen announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:00
12/09/19
12/09
15:00
12/09/19
15:00
General news
U.S.-China trade/tariff uncertainty is still present »

U.S.-China trade/tariff…

NVS

Novartis

$92.68

0.6 (0.65%)

14:53
12/09/19
12/09
14:53
12/09/19
14:53
Hot Stocks
Novartis says Kymriah demonstrates consistent efficacy, safety outcomes »

Novartis announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

GILD

Gilead

$67.11

0.02 (0.03%)

14:51
12/09/19
12/09
14:51
12/09/19
14:51
Hot Stocks
Gilead's Kite says results ZUMA-2 trial support regulatory filings »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMDA

Gamida Cell

$5.10

0.01 (0.20%)

14:49
12/09/19
12/09
14:49
12/09/19
14:49
Hot Stocks
Gamida Cell announces results from Phase 1 clinical study of GDA-201 »

Gamida Cell announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFIX

Stitch Fix

$25.05

0.92 (3.81%)

14:49
12/09/19
12/09
14:49
12/09/19
14:49
Options
Stitch Fix options imply 24.0% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 11

    Dec

  • 12

    Dec

  • 19

    Dec

GILD

Gilead

$67.08

-0.01 (-0.01%)

14:47
12/09/19
12/09
14:47
12/09/19
14:47
Hot Stocks
Gilead's Kite announces findings from ongoing post-marketing study of Yescarta »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUAN

Nuance

$17.55

-0.34 (-1.90%)

14:45
12/09/19
12/09
14:45
12/09/19
14:45
Options
Nuance call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

GS

Goldman Sachs

$222.17

-2.4 (-1.07%)

, SFTBF

SoftBank

$0.00

(0.00%)

14:41
12/09/19
12/09
14:41
12/09/19
14:41
Periodicals
SoftBank taps Goldman for $1.75B financing to help revive WeWork, Bloomberg says »

SoftBank (SFTBF) has…

GS

Goldman Sachs

$222.17

-2.4 (-1.07%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

  • 26

    Feb

CBL

CBL & Associates

$1.12

-0.025 (-2.18%)

14:36
12/09/19
12/09
14:36
12/09/19
14:36
Hot Stocks
CBL & Associates closes sale of interest in the Outlet Shoppes at Atlanta »

CBL Properties announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

14:25
12/09/19
12/09
14:25
12/09/19
14:25
Options
Berkshire Hathaway call volume above normal and directionally bullish »

Bullish option flow…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
12/09/19
12/09
14:17
12/09/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
12/09/19
12/09
14:16
12/09/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:15
12/09/19
12/09
14:15
12/09/19
14:15
General news
Treasury Action: yields are little changed »

Treasury Action: yields…

VWAGY

Volkswagen

$0.00

(0.00%)

14:08
12/09/19
12/09
14:08
12/09/19
14:08
Hot Stocks
Canada agency says VW charged with federal environmental law offences »

According to Environment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$88.77

-0.07 (-0.08%)

, ARQL

ArQule

$19.70

10.03 (103.72%)

14:07
12/09/19
12/09
14:07
12/09/19
14:07
Downgrade
Merck, ArQule rating change  »

ArQule downgraded to…

MRK

Merck

$88.77

-0.07 (-0.08%)

ARQL

ArQule

$19.70

10.03 (103.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 11

    Dec

  • 17

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.